Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$3.29
-$0.04(-1.36%)
At close: 4:00 PM EDT
$3.29
-$0.04(-1.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume671.33K
Average Volume (3M)2.20M
Market Cap
$262.55M
Enterprise Value$178.51M
Total Cash (Recent Filing)$236.88M
Total Debt (Recent Filing)$3.96M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 17, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding114,151,665
10 Day Avg. Volume1,569,139
30 Day Avg. Volume2,203,514
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue487.72
Enterprise Value/Gross Profit-116.29
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$12.18Price Target Upside270.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$289.42K
Bulls Say, Bears Say
Bulls Say
Regulatory DevelopmentFast Track status can support more frequent FDA interaction and streamline development for PSV359, improving the program’s ability to advance through clinical milestones. The designation also validates the relevance of its FAP-targeted approach in a cancer area with limited treatment options.
Radiopharmaceutical PlatformAn integrated platform spanning targeting, production, and delivery may give Perspective greater control over radiopharmaceutical development and supply execution. Its multi-program pipeline and stated intellectual-property infrastructure could support broader oncology applications and reinforce differentiation as programs mature.
Balance Sheet FlexibilityVery low leverage reduces financial distress pressure and preserves flexibility while the company funds clinical development. Growth in equity supports the asset base, giving Perspective more capacity to pursue milestones without the added constraints associated with substantial debt obligations.
Bears Say
Revenue ContractionMinimal and declining revenue shows that Perspective has not yet established meaningful commercial scale. With prior periods including zero reported revenue, the business remains dependent on successful clinical advancement and future commercialization rather than internally generated operating revenue.
Persistent Cash BurnSustained negative operating and free cash flow indicates that core activities and investment requirements continue to consume substantial liquidity. Unless profitability improves, ongoing development is likely to require continued funding, limiting financial resilience and increasing dependence on capital access.
Deep Operating LossesThe cost structure remains far ahead of current revenue, producing deeply negative profitability and returns. Persistent losses reduce the company’s ability to fund growth internally, increase reliance on its cash balance, and leave execution highly dependent on eventual clinical and commercial success.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $262.55M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 26 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Aug 10, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.031.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 114,151,665 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.18 (270.27% Upside)
$12.18 (270.27% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 86%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 41.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.04%
12-Months-Change
Fundamentals
Return on Equity
-41.56%
Trailing 12-Months
Asset Growth
26.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$12.18
▲(270.27% Upside)
Technical Analysis
Ownership Overview
21.63% Insiders
6.91% Mutual Funds
0.47% Other Institutional Investors
60.11% Public Companies and
Individual Investors